

## Health economics study with Prostatype® peerreviewed and approved for publishing in renown scientific journal

Prostatype Genomics AB announces that a health economics study with the company's gene test Prostatype® for diagnosed prostate cancer, which confirms that Prostatype® can contribute to just over 600 MSEK in annual health economic benefit in Sweden alone, has been peer-reviewed and approved for publishing in the renown scientific journal PharmacoEconomics. The study results were communicated in October 2024, and the study was conducted by the Institute for Health and Healthcare Economics (IHE). Publication is expected in the coming weeks.


"It is encouraging that this important health economics study, which states that Prostatype® can contribute with great benefit to both Swedish patients, the healthcare system and the society at large, has been approved for publication in what is considered to be the leading scientific reference journal for the practical application of health economics," says Prostatype Genomics' CEO Fredrik Rickman.

"It is common knowledge that there is a variation between different assessors of histopathology within the healthcare system. This has been brought to public attention in Sweden recently in connection with information about cases where women underwent unnecessary surgical removal of their uteruses. It is a parallel to the overtreatment that unfortunately occurs all too often in patients diagnosed with prostate cancer, which in many cases leads to lifelong side effects such as primarily impotence and incontinence. The effect of the histopathological variation can be minimised with a validated, standardised prognostic test like Prostatype® where the health economic benefit is also very clear," Fredrik Rickman continues.

"It is well known that the Swedish healthcare system is and has been under strong pressure, and that the use of the limited resources available must be utilized in an optimal way. It is therefore evident that the relevant Swedish authorities and healthcare regions now should work rapidly towards a more extensive use of Prostatype®, which would prove to be an obvious win-win for both patients' quality of life and the society at large," Fredrik Rickman concludes.

## About the health economics study with Prostatype®

The results of the IHE study were presented by Prostatype Genomics in a press release on October 3, 2024, which can be read <a href="https://example.com/hee/">here</a>. The study was further presented during the annual meeting of the Swedish Urological Association in Norrköping, Sweden, on October 3, 2024. In short, the IHE study concluded that a more extensive use of Prostatype®, and thus a scientifically supported improved risk classification of patients with established prostate cancer, can lead to significantly fewer radical treatments which often give rise to severe and lifelong side effects. This in turn creates extensive socioeconomic benefits compared to using the commonly used and recognized D'Amico risk classification tool.





## For more information, please contact:

Fredrik Rickman, CEO Prostatype Genomics AB

Telephone: +46 (0)73 049 77 01

Email: fredrik.rickman@prostatypegenomics.com

## **About Prostatype Genomics AB**

Prostatype® is a genomic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or no-treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institute and is provided by Prostatype Genomics AB.